Investigation – Page 21

Residue limit non-compliance during inspection prep: risk assessment for animal and food safety

Assessing Residue Limit Non-Compliance During Inspection Preparation: An Investigative Approach In the highly regulated pharmaceutical landscape, ensuring compliance with residue limits for veterinary medicines is paramount. Residue limit non-compliance can…

Labeling non-compliance during controlled drug manufacturing: regulatory enforcement risk mitigation

Addressing Labeling Non-Compliance Risks in Controlled Drug Manufacturing Labeling non-compliance in controlled drug manufacturing can lead to significant regulatory enforcement risks and potential impacts on patient safety. When labeling errors…

Stability failure during regulatory submission: regulatory communication strategy

Investigation Strategies for Addressing Stability Failures During Regulatory Submissions Stability failures during regulatory submission can jeopardize the approval process of veterinary medicines, leading to delays and increased costs. These failures…

Biologic stability failure (real-time/accelerated) during PPQ / process validation: single-use systems risk controls, leachables review, and supplier oversight actions

“`html Investigation into Biologic Stability Failures during PPQ Process Validation Biologic stability failures during real-time or accelerated stability testing can significantly impede process validation and batch release timelines. This article…

Chain of custody breach during controlled drug manufacturing: inspection-ready documentation

Addressing Breaches in Chain of Custody during Controlled Substance Manufacturing In the highly regulated sphere of pharmaceutical manufacturing, particularly concerning controlled substances, breaches in chain of custody can pose serious…

Stability failure during regulatory submission: GMP investigation and CAPA

Addressing Stability Failures in Regulatory Submissions: A Comprehensive GMP Investigation Stability failures encountered during regulatory submissions pose significant risks to ongoing pharmaceutical development, potentially delaying approvals and increasing costs. This…

Inventory reconciliation mismatch during warehousing: inspection-ready documentation

Addressing Inventory Reconciliation Mismatches in Warehousing: Effective Investigation Strategies In pharmaceutical manufacturing, maintaining an accurate inventory is not just a best practice; it’s a regulatory requirement. An inventory reconciliation mismatch…

Stability failure in veterinary product manufacturing: regulatory communication strategy

Understanding and Investigating Stability Failures in Veterinary Product Manufacturing Stability failure in veterinary product manufacturing can lead to significant quality issues, regulatory challenges, and ultimately harm to the patient or…

Finished product nitrosamine risk assessment gap during recall risk assessment: how to build a deviation package that passes an inspection deep-dive

“`html Identifying Gaps in Finished Product Nitrosamine Risk Assessments During Recall Procedures Nitrosamines have emerged as a significant concern in the pharmaceutical industry, primarily due to their potential carcinogenic properties.…

Sterility assurance gap during radiopharma production: regulatory deviation handling

Addressing Sterility Assurance Gaps in Radiopharmaceutical Production: A Comprehensive Investigation Guide The production of radiopharmaceuticals is a complex process that requires stringent adherence to sterility assurance principles. A deviation or…

Stability failure in veterinary product manufacturing: GMP investigation and CAPA

Investigating Stability Failures in Veterinary Product Manufacturing: A GMP Approach Stability failures in veterinary product manufacturing can lead to serious consequences, including regulatory non-compliance, compromised product efficacy, and potential harm…

Biosimilar process change without bridging study after cell line or upstream change: risk assessment for critical quality attributes and clinical impact

Assessing Risks from Biosimilar Process Changes Without Bridging Studies After Cell Line Adjustments In the dynamic field of biosimilar production, any process change—especially those made without a bridging study—poses significant…